Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 56.87

-2.2%

Dec 5 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Ian@SI who wrote (2992)	2/26/2001 1:59:56 PM
From: Biomaven	Read Replies (1) of 52153

Ian, My guess is that most of the junk DNA is indeed "commented out code" and other artifacts of the evolutionary process. Looking at the big picture, though, a part of the picture is not just what genes presently reside in the genome, but also what genes potentially reside in it after some mutations down the road. It may well be that a portion of the junk DNA has long-term significance - it may help determine the long-term evolution of the species. (Likely an aspect that pharmas and biotechs don't care much about). However, I'll bet there are indeed some crucial hidden jewels tucked away amidst the "junk DNA." Talk about needle in a haystack, though ... Peter (But remember that I'm a layman here too...)

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next